Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Semafor and Gizmodo. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 31d ago.
Quick answers
Why is "Kalshi comes for biopharma, with prediction markets for clinical trials and FDA " trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Kalshi bets on Wall Street Semafor · 45d ago
- Kalshi Is Set to Start Taking Bets on Drug Trials Gizmodo · 45d ago
Topics
Related trends
Kalshi's head of research weighs in on election betting, possible regulations
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Fired Trump Goon Ordered to Pay Up After Insider Trading Bust
A former White House teleprompter operator has been ordered to pay $172,000 following an insider trading bust involving bets on the Kalshi platform.
Whole Foods guacamole recall classified under FDA's highest risk level
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
9th Circuit sides with states in Kalshi gambling fight, potentially reviving Arizona's prosecution
A federal appeals court backs states, letting Nevada ban Kalshi and sparking a potential revival of Arizona’s prosecution of prediction markets.
FDA Authorizes Juul to Sell New E-Cigarette
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Whole Foods Recalls Popular Dips Across 13 States Due To Salmonella Contamination
Whole Foods has recalled 13,000 guacamole containers across 13 states after the FDA upgraded the Salmonella threat to its highest risk level.